ERBB2 and urinary bladder carcinoma: Hsp90 inhibitors at low concentrations, which did not exert cytocidal effects but inactivated erbB2, Akt, and NFkB, and efficiently sensitized bladder cancer cells to in vitro and in vivo CRT more effectively than sole or combined inhibition of erbB2 and Akt (Yoshida et al., 2011[61]).